The aim was to identify aBifidobacteriumstrain that improved the performance ofLimosilactobacillusreuteriDSM 17938. Initial tests showed thatBifidobacteriumlongumsubsp.longumstrains boosted the growth of DSM 17938 during in vivo-like conditions. Further characterization revealed that one of the strains, BG-L47, had better bile and acid tolerance compared to BG-L48, as well as mucus adhesion compared to both BG-L48 and the control strain BB536. BG-L47 also had the capacity to metabolize a broad range of carbohydrates and sugar alcohols. Mapping of glycoside hydrolase (GH) genes of BG-L47 and BB536 revealed many GHs associated with plant-fiber utilization. However, BG-L47 had a broader phenotypic fiber utilization capacity. In addition,B. longumsubsp.longumcells boosted the bioactivity of extracellular membrane vesicles (MV) produced byL. reuteriDSM 17938 during cocultivation. Secreted 5’ nucleotidase (5’NT), an enzyme that converts AMP into the signal molecule adenosine, was increased in MV boosted by BG-L47. The MV exerted an improved antagonistic effect on the pain receptor TRPV1 and increased the expression of the immune development markers IL-6 and IL-1ß in a PBMC model. Finally, the safety of BG-L47 was evaluated both by genome safety assessment and in a human safety study. Microbiota analysis showed that the treatment did not induce significant changes in the composition. In conclusion,B. longumsubsp.longumBG-L47 has favorable physiological properties, can boost the in vitro activity ofL. reuteriDSM 17938, and is safe for consumption, making it a candidate for further evaluation in probiotic studies.